The School of Pharmaceutical Sciences of Lovely Professional University has developed a new formulation, which is claimed to be useful in overcoming the side effects of the drugs used in treatment of deadly colon cancer.
It was developed indigenously at Lovely Professional University by Dean, Faculty of Applied Medical Sciences, Dr Monica Gulati and her team. Realizing the potential of the invention, an MOU has been signed between LPU and a premier pharmaceutical company Rhydburg, at Dehradun. Rhydburg is one of the premier drug manufacturers and exporters of pharmaceuticals- tablets, injections, beta lactam, syrups, capsules etc.
Highlighting the importance of the anti-cancer medicine Dr Gulati explained more about the side effects of colon cancer treatment. She informed, " In general, anticancer drugs affect cells that divide rapidly, especially, Blood cells, Cells in hair roots & Cells that line the digestive tract. When drugs affect these cells, patients are more likely to get infections, bruise, hair loss, poor appetite, nausea, vomiting, diarrhea, mouth & lip sores or feel very weak and tired.”
She said, “Almost similar effects can be during Radiation and Biological therapy. However, many of these side effects of colon cancer chemotherapy can be controlled with drugs. For this reason, our Department strived to invent the remedy and further collaborated with a top pharmaceutical company.”
Extending felicitations to Dr Gulati and her team, the Chancellor of University, Ashok Mittal said, "The research facilities at the University are being extended to aim at the world class innovations & research in the university. The present patent, which has already been published for 140 countries, has further motivated us to perform better."
He added, "During severe medical treatments, certain side effects of many medicines have devastating results, leading to an incalculable precious drain on human talent and resources. Such a development is indeed a great Endeavour towards welfare of humanity. Also we wanted that the medicine should actually be used and should not remain only as research.”
Speaking on the occasion, the Managing Director of Rhydburg, Ashok Monga, said: “With team of LPU coming out with such a needed medicine; we can easily make out that India is fast realizing its intellectual potential and the next era will see a lot more technological advancements from Indian Scientists like those at LPU."